Galectin Therapeutics (GALT) Net Income towards Common Stockholders (2010 - 2026)
Galectin Therapeutics' (GALT) quarterly Net Income towards Common Stockholders came in at -$5.1 million in Q1 2026, up 47.25% year-on-year from -$3.4 million in Q1 2025, and up 8.9% quarter-over-quarter from -$5.6 million in Q4 2025.
Galectin Therapeutics (GALT) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$5.1 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 47.25% year-over-year to -$5.1 million in Q1 2026; TTM through Mar 2026 was -$26.4 million, a 41.65% increase from a year earlier, with the FY2025 full-year figure at -$31.0 million, up 34.38% from the prior year.
- Net Income towards Common Stockholders rose to -$5.1 million in Q1 2026 per GALT's latest filing, from -$5.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$5.1 million in Q1 2026 and bottomed at -$14.0 million in Q3 2023.
- The 5-year median for Net Income towards Common Stockholders is -$9.9 million (2022), against an average of -$9.8 million.
- Across the five-year window, Net Income towards Common Stockholders sank 63.63% in 2023 and jumped 53.77% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$10.7 million in 2022, then increased by 5.97% to -$10.1 million in 2023, then fell by 19.58% to -$12.0 million in 2024, then soared by 53.77% to -$5.6 million in 2025, then climbed by 8.9% to -$5.1 million in 2026.
- Per Business Quant, the three latest GALT Net Income towards Common Stockholders figures stand at -$5.1 million (Q1 2026), -$5.6 million (Q4 2025), and -$8.2 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Galectin Therapeutics | 225.30 Mn | 225.30 Mn | - | -5.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.07 Mn |
| Dec 31, 2025 | -5.56 Mn |
| Sep 30, 2025 | -8.22 Mn |
| Jun 30, 2025 | -7.58 Mn |
| Mar 31, 2025 | -9.61 Mn |
| Dec 31, 2024 | -12.03 Mn |
| Sep 30, 2024 | -11.24 Mn |
| Jun 30, 2024 | -12.44 Mn |
| Mar 31, 2024 | -11.50 Mn |
| Dec 31, 2023 | -10.06 Mn |
| Sep 30, 2023 | -14.04 Mn |
| Jun 30, 2023 | -9.18 Mn |
| Mar 31, 2023 | -11.53 Mn |
| Dec 31, 2022 | -10.70 Mn |
| Sep 30, 2022 | -8.58 Mn |
| Jun 30, 2022 | -9.68 Mn |
| Mar 31, 2022 | -9.92 Mn |
| Dec 31, 2021 | -7.29 Mn |
| Sep 30, 2021 | -8.56 Mn |
| Jun 30, 2021 | -8.51 Mn |